Pancreatic lipase Inhibitors
1 drugsAbout Pancreatic lipase
Pancreatic lipase is a digestive enzyme that breaks down dietary fats into absorbable molecules. Inhibiting this enzyme reduces fat absorption in the intestines, impacting overall metabolism.
Pancreatic lipase is a therapeutic target for managing metabolic disorders like obesity by reducing fat absorption. Currently, there is no genetic evidence directly linking pancreatic lipase to specific diseases.
Pancreatic lipase is targeted by one FDA-approved drug, Xenical (orlistat), a small molecule. Cheplapharm is the sole company with an approved drug targeting this enzyme in the metabolic therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top Pancreatic lipase Drugs
Cheplapharm is the only company with an approved drug targeting pancreatic lipase.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market viability.
Pancreatic lipase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Pancreatic lipase, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies and potentially improve efficacy.
Pancreatic lipase Clinical Trials 24 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 9 | 4 | 2 | 3 | 67% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 10 | 6 | 2 | 2 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pancreatic lipase Drug Approval Timeline (1999 - 1999)
The first and only drug, Xenical, was approved in 1999.
The lack of recent approvals suggests market saturation or challenges in developing improved pancreatic lipase inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting Pancreatic lipase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities